INTERVENTION 1:	Intervention	0
Standard Breast Irradiation	Intervention	1
breast	UBERON:0000310	9-15
radiation therapy: Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.	Intervention	2
breast	UBERON:0000310	28-34
rate	BAO:0080019	89-93
day	UO:0000033	109-112
day	UO:0000033	116-119
week	UO:0000034	123-127
week	UO:0000034	134-138
INTERVENTION 2:	Intervention	3
Breast Radiation Plus Regional Radiation	Intervention	4
breast	UBERON:0000310	0-6
regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)	Intervention	5
Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.	Intervention	6
breast	UBERON:0000310	0-6
rate	BAO:0080019	83-87
day	UO:0000033	103-106
day	UO:0000033	110-113
week	UO:0000034	117-121
week	UO:0000034	128-132
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically proven invasive carcinoma of the breast	Eligibility	1
carcinoma	HP:0030731,DOID:305	31-40
breast	UBERON:0000310	48-54
No evidence of T4, N2-3, or M1 disease prior to surgery	Eligibility	2
m1	CHEBI:34826	28-30
disease	DOID:4,OGMS:0000031	31-38
surgery	OAE:0000067	48-55
Node positive or high-risk node negative	Eligibility	3
Prior breast-conserving therapy (BCT) (e.g., lumpectomy, partial mastectomy, or segmental mastectomy) and axillary node dissection or sentinel node biopsy required and must be a candidate for breast radiotherapy after BCT	Eligibility	4
breast	UBERON:0000310	6-12
breast	UBERON:0000310	192-198
radiotherapy	OAE:0000235	199-211
Normally patients should have microscopically clear resection margins and those with positive margins should undergo reexcision	Eligibility	5
Patients with microscopically focally positive margins (defined as no greater than 3 times high power fields) are candidates for breast radiotherapy plus a boost to the lumpectomy site	Eligibility	6
breast	UBERON:0000310	129-135
radiotherapy	OAE:0000235	136-148
site	BFO:0000029	180-184
Patients with prior sentinel node dissection eligible if node negative, but still meet high-risk criteria	Eligibility	7
If node positive, then a level I and II axillary dissection must be performed	Eligibility	8
No evidence of residual disease in axilla after dissection	Eligibility	9
disease	DOID:4,OGMS:0000031	24-31
Must be treated with currently accepted adjuvant systemic chemotherapy and/or hormonal therapy	Eligibility	10
adjuvant	CHEBI:60809	40-48
High risk of regional and systemic recurrence due to one of the following:	Eligibility	11
Pathologically positive axillary lymph nodes	Eligibility	12
lymph	UBERON:0002391	33-38
Pathologically negative axillary lymph nodes with one of the following:	Eligibility	13
lymph	UBERON:0002391	33-38
Primary tumor greater than 5 cm	Eligibility	14
Primary tumor greater than 2 cm and less than 10 axillary lymph nodes excised and one of the following:	Eligibility	15
lymph	UBERON:0002391	58-63
Estrogen receptor negative	Eligibility	16
estrogen	CHEBI:50114,BAO:0000760	0-8
receptor	BAO:0000281	9-17
Skarf-Bloom-Richardson grade 3	Eligibility	17
Lymphovascular invasion	Eligibility	18
Hormone receptor status:	Eligibility	19
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Estrogen and progesterone receptor status known	Eligibility	20
estrogen	CHEBI:50114,BAO:0000760	0-8
progesterone	CHEBI:17026	13-25
receptor	BAO:0000281	26-34
PATIENT CHARACTERISTICS:	Eligibility	21
patient	HADO:0000008,OAE:0001817	0-7
Age:	Eligibility	22
age	PATO:0000011	0-3
16 and over	Eligibility	23
Sex:	Eligibility	24
Female	Eligibility	25
female	PATO:0000383	0-6
Menopausal status:	Eligibility	26
Premenopausal or postmenopausal	Eligibility	27
Performance status:	Eligibility	28
ECOG 0-2	Eligibility	29
Life expectancy:	Eligibility	30
At least 5 years	Eligibility	31
Hematopoietic:	Eligibility	32
Not specified	Eligibility	33
Hepatic:	Eligibility	34
SGOT and/or SGPT no greater than 3 times upper limit of normal (ULN)*	Eligibility	35
Alkaline phosphatase no greater than 3 times ULN* NOTE: * Patients with laboratory values greater than 3 times ULN may still be eligible if no metastatic disease by imaging examinations	Eligibility	36
phosphatase	GO:0016791,BAO:0000295	9-20
disease	DOID:4,OGMS:0000031	154-161
Renal:	Eligibility	37
No serious nonmalignant renal disease	Eligibility	38
disease	DOID:4,OGMS:0000031	30-37
Cardiovascular:	Eligibility	39
No serious nonmalignant cardiovascular disease	Eligibility	40
disease	DOID:4,OGMS:0000031	39-46
Pulmonary:	Eligibility	41
No serious nonmalignant pulmonary disease	Eligibility	42
disease	DOID:4,OGMS:0000031	34-41
Other:	Eligibility	43
Not pregnant or nursing	Eligibility	44
Fertile patients must use effective contraception	Eligibility	45
No other serious nonmalignant disease (e.g., systemic lupus erythematosus or scleroderma) that would preclude definitive surgery or radiotherapy	Eligibility	46
disease	DOID:4,OGMS:0000031	30-37
systemic lupus erythematosus	HP:0002725,DOID:9074	45-73
scleroderma	HP:0100324,DOID:419,DOID:418	77-88
surgery	OAE:0000067	121-128
radiotherapy	OAE:0000235	132-144
No other malignancy except:	Eligibility	47
Nonmelanomatous skin cancer	Eligibility	48
skin cancer	DOID:4159	16-27
Carcinoma in situ of the cervix or endometrium	Eligibility	49
carcinoma	HP:0030731,DOID:305	0-9
endometrium	UBERON:0001295	35-46
Contralateral noninvasive breast cancer (unless prior radiotherapy to the contralateral breast)	Eligibility	50
breast cancer	DOID:1612	26-39
radiotherapy	OAE:0000235	54-66
breast	UBERON:0000310	26-32
breast	UBERON:0000310	88-94
Invasive carcinoma of the cervix, endometrium, colon, thyroid, or melanoma that was curatively treated at least 5 years prior to study participation	Eligibility	51
carcinoma	HP:0030731,DOID:305	9-18
endometrium	UBERON:0001295	34-45
colon	UBERON:0001155	47-52
melanoma	HP:0002861,DOID:1909	66-74
No psychiatric or addictive disorder that would preclude informed consent or study compliance	Eligibility	52
disorder	OGMS:0000045	28-36
PRIOR CONCURRENT THERAPY:	Eligibility	53
Biologic therapy:	Eligibility	54
Not specified	Eligibility	55
Chemotherapy:	Eligibility	56
See Disease Characteristics	Eligibility	57
disease	DOID:4,OGMS:0000031	4-11
Concurrent standard adjuvant chemotherapy allowed	Eligibility	58
adjuvant	CHEBI:60809	20-28
Endocrine therapy:	Eligibility	59
See Disease Characteristics	Eligibility	60
disease	DOID:4,OGMS:0000031	4-11
Concurrent standard adjuvant hormonal therapy allowed	Eligibility	61
adjuvant	CHEBI:60809	20-28
Radiotherapy:	Eligibility	62
radiotherapy	OAE:0000235	0-12
See Disease Characteristics	Eligibility	63
disease	DOID:4,OGMS:0000031	4-11
Surgery:	Eligibility	64
surgery	OAE:0000067	0-7
See Disease Characteristics	Eligibility	65
disease	DOID:4,OGMS:0000031	4-11
Outcome Measurement:	Results	0
Overall Survival	Results	1
Duration of study	Results	2
duration	PATO:0001309	0-8
Time frame: 10 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Standard Breast Irradiation	Results	5
breast	UBERON:0000310	26-32
Arm/Group Description: radiation therapy: Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.	Results	6
breast	UBERON:0000310	51-57
rate	BAO:0080019	112-116
day	UO:0000033	132-135
day	UO:0000033	139-142
week	UO:0000034	146-150
week	UO:0000034	157-161
Overall Number of Participants Analyzed: 916	Results	7
Measure Type: Number	Results	8
Unit of Measure: percentage of alive at 10 years  82        (79 to 84)	Results	9
Results 2:	Results	10
Arm/Group Title: Breast Radiation Plus Regional Radiation	Results	11
breast	UBERON:0000310	17-23
Arm/Group Description: regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)	Results	12
Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.	Results	13
breast	UBERON:0000310	0-6
rate	BAO:0080019	83-87
day	UO:0000033	103-106
day	UO:0000033	110-113
week	UO:0000034	117-121
week	UO:0000034	128-132
Overall Number of Participants Analyzed: 916	Results	14
Measure Type: Number	Results	15
Unit of Measure: percentage of alive at 10 years  83        (80 to 85)	Results	16
Adverse Events 1:	Adverse Events	0
Total: 1/927 (0.11%)	Adverse Events	1
Secondary Malignancy 1/927 (0.11%)	Adverse Events	2
Adverse Events 2:	Adverse Events	3
Total: 3/893 (0.34%)	Adverse Events	4
Secondary Malignancy 3/893 (0.34%)	Adverse Events	5
